Currently, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in
patients with non-valvular atrial fibrillation (NVAF). They are characterized by a more …

The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia,
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …

Background: To review data from the pivotal phase III trials evaluating the efficacy and safety
of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in patients with …

Background: The aim of the study was to evaluate the efficacy and safety of direct oral
anticoagulants (DOACs) in a subgroup of patients with atrial fibrillation (AF), CHADS2 …

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. Strokes that occur
as a complication of AF are usually more severe and associated with a higher disability or …

Atrial fibrillation (AF) is considered the most common sustained cardiac arrhythmia, and it is
associated with a significant risk of adverse events, especially ischemic stroke. Oral …

Purpose To identify the proportion of real-life patients with atrial fibrillation (AF) eligible for
direct oral anticoagulant (DOAC) therapy, based on the inclusion and exclusion criteria used …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. It was estimated to affect up to
6.1 million Americans in 2010, and since AF is more common with increasing age, it is …

Background In recent years, direct-acting oral anticoagulants (DOACs) have entered clinical
practice for stroke prevention in non-valvular atrial fibrillation or prevention and treatment of …

Introduction Direct oral anticoagulant (DOAC) agents are established as the anticoagulation
strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard …